Augury Medical GmbH

Pacemakers help millions of patients regulate their heart rhythm, yet more than 20% of recipients develop pacing-induced heart failure within a few years of implantation. Today, this complication is usually detected only after symptoms appear, when the disease is already advanced and costly to treat. Augury Medical addresses this challenge with a software tool that predicts individual patient risk using standard ECG data, providing doctors with a risk assessment and visual heart map to support treatment decisions. Leveraging existing reimbursement pathways offers a large beachhead market of CHF 500M+, with plans to expand into adjacent clinical fields. By identifying high-risk patients earlier, Augury Medical enables preventive care and helps reduce the long-term burden of heart failure.